vs

Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and GREENPOWER MOTOR Co INC. (GP). Click either name above to swap in a different company.

Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $7.2M, roughly 1.5× GREENPOWER MOTOR Co INC.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -65.6%, a 89.1% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -11.5%).

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

ABUS vs GP — Head-to-Head

Bigger by revenue
ABUS
ABUS
1.5× larger
ABUS
$10.7M
$7.2M
GP
Growing faster (revenue YoY)
ABUS
ABUS
+533.7% gap
ABUS
522.2%
-11.5%
GP
Higher net margin
ABUS
ABUS
89.1% more per $
ABUS
23.5%
-65.6%
GP

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
ABUS
ABUS
GP
GP
Revenue
$10.7M
$7.2M
Net Profit
$2.5M
$-4.7M
Gross Margin
14.6%
Operating Margin
13.9%
Net Margin
23.5%
-65.6%
Revenue YoY
522.2%
-11.5%
Net Profit YoY
112.7%
-2.1%
EPS (diluted)
$0.01
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABUS
ABUS
GP
GP
Q2 25
$10.7M
Q4 24
$7.2M
Q3 24
$5.3M
Q2 24
$3.0M
Q4 23
$2.1M
$8.2M
Q3 23
$4.7M
$8.4M
Q2 23
$4.7M
$17.6M
Q1 23
$6.7M
Net Profit
ABUS
ABUS
GP
GP
Q2 25
$2.5M
Q4 24
$-4.7M
Q3 24
$-4.7M
Q2 24
$-5.4M
Q4 23
$-4.6M
Q3 23
$-20.1M
$-4.3M
Q2 23
$-17.1M
$-2.8M
Q1 23
$-16.3M
Gross Margin
ABUS
ABUS
GP
GP
Q2 25
Q4 24
14.6%
Q3 24
8.6%
Q2 24
7.4%
Q4 23
16.6%
Q3 23
14.6%
Q2 23
15.9%
Q1 23
Operating Margin
ABUS
ABUS
GP
GP
Q2 25
13.9%
Q4 24
Q3 24
Q2 24
Q4 23
-967.2%
Q3 23
-462.8%
Q2 23
-395.3%
Q1 23
-260.4%
Net Margin
ABUS
ABUS
GP
GP
Q2 25
23.5%
Q4 24
-65.6%
Q3 24
-87.9%
Q2 24
-179.8%
Q4 23
-56.9%
Q3 23
-431.6%
-50.4%
Q2 23
-367.5%
-16.0%
Q1 23
-244.3%
EPS (diluted)
ABUS
ABUS
GP
GP
Q2 25
$0.01
Q4 24
$-0.17
Q3 24
$-0.18
Q2 24
$-0.21
Q4 23
$-0.12
$-0.19
Q3 23
$-0.12
$-0.17
Q2 23
$-0.10
$-0.11
Q1 23
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABUS
ABUS
GP
GP
Cash + ST InvestmentsLiquidity on hand
$37.4M
$621.1K
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$83.0M
$2.1M
Total Assets
$103.3M
$37.4M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABUS
ABUS
GP
GP
Q2 25
$37.4M
Q4 24
$621.1K
Q3 24
$116.9K
Q2 24
$528.3K
Q4 23
$126.0M
$4.0M
Q3 23
$17.5M
$2.0M
Q2 23
$27.2M
$1.5M
Q1 23
$40.6M
Total Debt
ABUS
ABUS
GP
GP
Q2 25
$0
Q4 24
Q3 24
Q2 24
Q4 23
$0
Q3 23
$0
Q2 23
$0
Q1 23
$0
Stockholders' Equity
ABUS
ABUS
GP
GP
Q2 25
$83.0M
Q4 24
$2.1M
Q3 24
$4.2M
Q2 24
$8.6M
Q4 23
$106.0M
$18.1M
Q3 23
$119.3M
$22.3M
Q2 23
$134.7M
$26.2M
Q1 23
$143.9M
Total Assets
ABUS
ABUS
GP
GP
Q2 25
$103.3M
Q4 24
$37.4M
Q3 24
$39.4M
Q2 24
$43.5M
Q4 23
$144.4M
$50.2M
Q3 23
$158.6M
Q2 23
$176.8M
Q1 23
$191.2M
Debt / Equity
ABUS
ABUS
GP
GP
Q2 25
0.00×
Q4 24
Q3 24
Q2 24
Q4 23
0.00×
Q3 23
0.00×
Q2 23
0.00×
Q1 23
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABUS
ABUS
GP
GP
Operating Cash FlowLast quarter
$-15.7M
$-1.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-6.24×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABUS
ABUS
GP
GP
Q2 25
$-15.7M
Q4 24
$-1.1M
Q3 24
$-1.3M
Q2 24
$-3.2M
Q4 23
$-17.3M
$1.4M
Q3 23
$-21.8M
$-5.4M
Q2 23
$-19.6M
$7.8M
Q1 23
$-27.3M
Free Cash Flow
ABUS
ABUS
GP
GP
Q2 25
Q4 24
Q3 24
Q2 24
Q4 23
Q3 23
$-21.8M
Q2 23
$-20.4M
Q1 23
$-27.4M
FCF Margin
ABUS
ABUS
GP
GP
Q2 25
Q4 24
Q3 24
Q2 24
Q4 23
Q3 23
-468.4%
Q2 23
-439.0%
Q1 23
-410.0%
Capex Intensity
ABUS
ABUS
GP
GP
Q2 25
0.0%
Q4 24
Q3 24
Q2 24
Q4 23
0.0%
Q3 23
0.7%
Q2 23
18.5%
Q1 23
1.7%
Cash Conversion
ABUS
ABUS
GP
GP
Q2 25
-6.24×
Q4 24
Q3 24
Q2 24
Q4 23
Q3 23
Q2 23
Q1 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons